Trial Profile

Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DTaP poliovirus vaccine (Primary) ; DTaP vaccine (Primary) ; Poliovirus vaccine inactivated; Poliovirus vaccine inactivated
Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
Focus Adverse reactions
Sponsors Sanofi; Sanofi Pasteur

29 Sep 2008 Status changed from active, no longer recruiting to completed.
21 Sep 2008 Planned end date identified as Oct 2007, as reported by ClinicalTrials.gov.
17 Oct 2006 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com